Skip to main content
Premium Trial:

Request an Annual Quote

LIMS Provider LabLynx Sues Accelrys for Trademark Counterfeiting, Infringement

NEW YORK (GenomeWeb News) — Laboratory management information system provider LabLynx has sued Accelrys for trademark counterfeiting, trademark infringement, and domain name cyberpiracy, among other things, according to recently filed court documents.

In a complaint filed with the US District Court for the Northern District of Georgia, LabLynx, based in Smyrna, Ga., said that in 2010 it created an online community for the scientific, laboratory, and healthcare fields at the URL Members of the site can exchange ideas, promote their services, collaborate on projects, and share applications through the site, LabLynx said.

The company also owns US Trademark Registration 4,201,907, issued on Sept. 4, 2012, and covering the mark and logo.

LabLynx alleges that Accelrys is currently using the mark "Sciencecloud" in the US to identify its information management and collaboration workspace offered as software-as-a-service, and advertises and promotes these services at the website Accelrys' services are "advertised and sold to members of the laboratory and scientific communities … allow members to collaborate and share data … and are marketed and sold to the same category of consumers" as LabLynx's services, LabLynx alleges in its complaint.

Further, LabLynx alleges that Accelrys began using "Sciencecloud" as a mark subsequent to Jan. 24, 2012, the filing date of the application resulting in LabLynx's registration. It also said that on Feb. 20 of this year it sent Accelrys a letter informing it of the registered "Scicloud" marks and informing Accelrys that it was infringing LabLynx's trademark rights by using the "Sciencecloud" mark.

As such, LabLynx is suing Accelrys for use of a counterfeit mark; infringement of a registered trademark; federal unfair competition; common law trademark infringement and unfair competition; violation of the Georgia Uniform Deceptive Trade Practices Act; and violation of the Anticybersquatting Consumer Protection Act.

LabLynx is asking the court to preliminarily and permanently enjoin and restrain Accelrys from offering or providing services under the "Sciencecloud" mark, "or any other designation, trademark, or service mark that is likely to cause confusion, mistake, or deception as to the source or sponsorship of [Accelrys'] services."

LabLynx is also requesting that the domain name be transferred to LabLynx, and it is seeking monetary compensation comprising profits received by Accelrys under the "Sciencecloud" mark in the US; damages proven at trial related to the alleged trademark infringement and unfair competition; and statutory damages. LabLynx is also requesting that any profits or damages assessed against Accelrys be trebled.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.